Encure Biotherapeutics is a US-based, AI-native cardiovascular therapeutics company engineering organ-targeted medicines for heart failure.

We begin with HFpEF, a condition that has resisted conventional drug development because it is not a single disease, but a convergence of inflammatory, metabolic, fibrotic, and microvascular dysfunction. Addressing it requires a fundamentally different approach.

Encure has built a closed-loop discovery and translation platform that integrates proprietary AI, advanced molecular modeling, human cardiac organoids, and targeted nanoparticle delivery systems. This platform is designed to address complex, multi-pathway diseases from the outset—moving beyond traditional single-target strategies.

The company is led by a US-based team of scientists and clinicians. The founding team consists of US citizens and permanent residents, and Encure is focused on building proprietary IP and clinical-stage assets within the US biotech ecosystem.

Encure Biotherapeutics

Org chart

Teams

Offices

Encure Biotherapeutics

Org chart

Teams

Offices

Related companies